Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
Leukemia & Lymphoma|July 29, 2016
Measurement of Soluble Interleukin 2 Receptor in Sera of Adult Patients with Hematological or Solid MalignanciesA Delforge, M Bernier, E Bosmans, et al.
Osteoarthritis and Cartilage|November 18, 2008
ADAMTS5-/- mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changesS M Botter, S S Glasson, B Hopkins, et al.
Blood|January 1, 1996
Human cytomegalovirus increases constitutive production of interleukin-6 and leukemia inhibitory factor by bone marrow stromal cellsL Lagneaux, A Delforge, R Snoeck, et al.
Antimicrobial Agents and Chemotherapy|October 3, 2012
Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndromeM Vaes, M Hites, F Cotton, et al.
Bone Marrow Transplantation|April 28, 1999
Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?C Jacquy, F Lambert, A Soree, et al.
Journal of Immunological Methods|July 3, 1990
Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV)D Bron, A Delforge, L Lagneaux, et al.
Blood|April 1, 1991
Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantationT Philip, F Chauvin, J Armitage, et al.
Blood Cells, Molecules & Diseases|November 6, 2004
Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted managementP Lewalle, A Delforge, M Aoun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1991
PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)T Philip, F Chauvin, D Bron, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1989
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumorsR A Stahel, J P Sculier, L M Jost, et al.
Pageof 20